SAN DIEGO, Oct. 18, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it has been granted Japanese Patent No.
6404118, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE
VARIANTS. The patent provides intellectual property protection for
the Company's Switch-Blocker technology which is core to Biocept's
Target Selector™ assays for analysis using real-time PCR,
Sanger sequencing and
next-generation sequencing.
"This latest patent further expands the global intellectual
property position for Biocept's rare mutation detection technology,
which already includes patents in the US, China, Australia, and Europe," said Lyle
Arnold, Ph.D., Biocept's Chief Scientific Officer. "Our
Switch-Blocker technology enables the ultra-sensitive detection of
rare genetic events, and is particularly useful for detecting and
monitoring rare cancer-associated mutations and alterations for use
in Biocept's liquid biopsy assays. This technology works with
Biocept's other technologies for blood collection and CTC capture
and analysis."
Michael Nall, Biocept's President
and CEO, added, "An important strategic initiative is to continue
to expand our patent protection around the world, and this new
patent strengthens the opportunity for Biocept to develop business
in major global markets such as Japan. We now have 30 issued patents for our
core technologies, and we intend to leverage our intellectual
property position in new territories as opportunities arise."
About Biocept
Biocept, Inc. is a molecular
diagnostics company with commercialized assays for lung, breast,
gastric, colorectal and prostate cancers, and melanoma. The
Company leverages its proprietary liquid biopsy technology to
provide physicians with clinically actionable information for
treating and monitoring patients diagnosed with cancer.
Biocept's patented Target Selector™ liquid biopsy technology
platforms capture and analyze tumor-associated molecular markers on
circulating tumor cells (CTCs) and in circulating tumor DNA
(ctDNA). With thousands of tests performed, the platform has
demonstrated the ability to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
news release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
improve the outcomes of cancer patients, our ability to develop
business in major global markets such as Japan and to leverage our intellectual
property position in new territories , the utility and
effectiveness of our intellectual property protections, and our
ability to broaden and leverage our intellectual property in the
future, , such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
Securities and Exchange Commission (SEC) filings. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
news release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC at
www.sec.gov
Investor
Contact:
|
Media
Contact:
|
LHA
|
Trevelino/Keller
|
Jody
Cain
|
Colleen
Murphy
|
Jcain@lhai.com
|
cmurphy@trevelinokeller.com
|
310-691-7100
|
404-214-0722, Ext.
109
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-obtains-japanese-patent-for-its-target-selector-oncogene-mutation-enrichment-and-detection-platform-300733445.html
SOURCE Biocept, Inc.